Bicara Therapeutics Inc. Common Stock
BCAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.6B
Close$
$1.74
93% downside
Current Fair Value
93% downsideOvervalued by 93% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.60 Billion |
|---|---|
| Enterprise Value | $1.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.52 |
| Beta | -0.75 |
| Outstanding Shares | 67,925,963 |
Return
| Return on Equity | -39.54% |
|---|---|
| Return on Assets | -36.19% |
| Return on Invested Capital | -41.18% |
Valuation & Multiples
| P/E Ratio | -7.83 |
|---|---|
| PEG | -7.65 |
| Price to Sales | - |
| Price to Book Ratio | 4.16 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.77 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.77
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.9485▲ 2.65% |
|---|---|
| Total Calls | 64,100▲ 2.07% |
| Total Puts | 189,000▲ 3.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 119.37%▼ 10.96% |
|---|---|
| Total Invested | $2.14B▲ 53.32% |
| Investors Holding | 180▲ 26.00% |
ESG Score
No data
About Bicara Therapeutics Inc. Common Stock
55 employees
CEO: Ms. Claire Mazumdar Clemon M.B.A., Ph.D. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR)...